Soleno Therapeutics stock overview

Soleno Therapeutics (SLNO) has drawn fresh attention after a sharp 32.3% one day move, capping a month gain of 31.7%. That kind of short term swing naturally raises valuation and risk questions for investors.

The sharp 32.3% one day share price return and 71.7% 7 day share price return come after a 10.8% year to date share price gain, set against a 1 year total shareholder return of about 25% decline and a very large 3 year total shareholder return. Momentum has clearly picked up again in the short term.

If this kind of move has you looking beyond a single rare disease name, it could be a good moment to see what else is moving in healthcare focused AI, starting with 37 healthcare AI stocks.

With Soleno now valued at about US$2.0b and trading at US$52.25, while sitting at a heavy discount to analyst and intrinsic estimates, you have to ask: is this a rare buying window, or is the market already pricing in future growth?

Most Popular Narrative: 54% Undervalued

Soleno Therapeutics last closed at $52.25, while the most followed narrative pegs fair value at about $113.54, creating a wide gap that hinges on a handful of powerful growth drivers.

Rapid uptake of VYKAT XR as the first and only FDA approved treatment for PWS related hyperphagia, with more than 1,000 patient start forms and 764 active patients within six months, supports a path to sustained revenue growth as penetration into an estimated 10,000 patient U.S. market increases.

Want to see what justifies that kind of gap between price and fair value? The narrative leans heavily on aggressive revenue build, margin expansion and a future earnings multiple that assumes real scale. The exact mix of those assumptions is where the story gets interesting.

Result: Fair Value of $113.54 (UNDERVALUED)

However, this story can shift quickly if launch momentum stalls or if safety concerns prompt more early discontinuations than the narrative assumes.

Another way to look at valuation

Analysts see Soleno as 54% undervalued, yet the current P/E of 131.7x is far above the US Biotechs industry at 16x, the peer average at 24.4x and even the fair ratio of 25.9x. That kind of gap can signal risk as much as opportunity. Which side do you think it sits on?

Next Steps

With sentiment split between a sharp recent rebound and richer valuation multiples, it makes sense to check the details yourself and move quickly while opinions are forming. To balance the concerns with the upside case, start with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Soleno has caught your eye, do not stop there. Use the screener to quickly surface other candidates that might fit your return and risk preferences.

• Target compelling value by checking companies that appear underpriced on quality and fundamentals through the 62 high quality undervalued stocks.
• Prioritize resilience by reviewing businesses with strong finances and healthy balance sheets using the solid balance sheet and fundamentals stocks screener (40 results).
• Get ahead of the crowd by scanning the screener containing 25 high quality undiscovered gems before others spot them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.